VIRI: Enrollment Complete in FORTRESS Trial; Results Expected in September 2022…
By David Bautz, PhD
NASDAQ:VIRI
READ THE FULL VIRI RESEARCH REPORT
Benzinga ·
Get all your news in one place.
100's of premium titles.
One app.
Start reading
One app.
Get all your news in one place.
100's of premium titles. One news app.
The Latest Breaking News from VIRI
Virios Therapeutics: Q1 Earnings Insights
Virios Therapeutics (NASDAQ:VIRI) reported its Q1 earnings results on Thursday, May 12, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Benzinga ·
Virios Therapeutics: Q4 Earnings Insights
Virios Therapeutics (NASDAQ:VIRI) reported its Q4 earnings results on Thursday, March 17, 2022 at 07:00 AM.
Here's what investors need to know about the announcement.
Benzinga ·
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Coverage From
Benzinga
People
From analysis to the latest developments in health,
read the most diverse news in one place.
read the most diverse news in one place.
Organisations
Read news from The Economist, FT, and more,
with one subscription
with one subscription
Fourteen days free
Download the app
One app. One membership.
100+ trusted global sources.
100+ trusted global sources.
